Promotional Information

This volume presents step-by-step techniques for researchers that will predict the structure and potential function of proteins by identifying its coding sequence

Table of Contents

Proteomics technologies for the global identification and quantification of proteins
Ian A. Brewis and P. Brennan

Targeted metabolomics and mass spectrometry
E. Dudley, M. Yousef, Y. Wang, W.J. Griffiths

Mechanisms of Protein Circular Dichroism: Insights from Computational Modelling
Tatyana Karabencheva and Christo Christov

Fine architecture and mutation mapping of human brain inhibitory system ligand gated ion channels by high-throughput homology modeling
Jonathan G. L. Mullins, Seo-Kyung Chung and Mark I. Rees

Positive and Negative Modulation of Nicotinic Receptors
Hugo R. Arias

Sonochemically Born Proteinaceous Micro- and Nanocapsules

Elena D. Vassileva and Neli S. Koseva

About the Author

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.